Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

被引：94

作者：

Spiegel, Jay Y. ^{[1
]}

Dahiya, Saurabh ^{[2
]}

Jain, Michael D. ^{[3
]}

Tamaresis, John ^{[1
]}

Nastoupil, Loretta J. ^{[4
]}

Jacobs, Miriam T. ^{[5
,6
]}

Ghobadi, Armin ^{[5
,6
]}

Lin, Yi ^{[7
]}

Lunning, Matthew ^{[8
]}

Lekakis, Lazaros ^{[9
]}

Reagan, Patrick ^{[10
]}

Oluwole, Olalekan ^{[11
]}

McGuirk, Joseph ^{[12
]}

Deol, Abhinav ^{[13
]}

Goy, Andre ^{[14
]}

Vu, Khoan ^{[15
]}

Andreadis, Charalambos ^{[15
]}

Munoz, Javier ^{[16
]}

Bennani, N. Nora ^{[7
]}

Vose, Julie M. ^{[8
]}

Dorritie, Kathleen A. ^{[17
]}

Neelapu, Sattva S. ^{[4
]}

Locke, Frederick L. ^{[3
]}

Rapoport, Aaron P. ^{[2
]}

Hill, Brian T. ^{[18
]}

Miklos, David B. ^{[1
]}

机构：

[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA

[2] Univ Maryland, Sch Med, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] Siteman Canc Ctr, St Louis, MO USA

[7] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[8] Univ Nebraska Med Ctr, Omaha, NE USA

[9] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[10] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

[11] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[12] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[13] Wayne State Univ, Karmanos Ctr Inst, Detroit, MI USA

[14] Hackensack Meridian Hlth, John Theurer Canc Ctr, Hackensack, NJ USA

[15] Univ Calif San Francisco, Dept Med, Med Ctr, Div Hematol Oncol, San Francisco, CA 94143 USA

[16] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[17] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[18] Cleveland Clin, Div Hematol & Med Oncol, Cleveland, OH 44106 USA

来源：

BLOOD | 2021年 / 137卷 / 13期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1182/blood.2020006245

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1832 / 1835

页数：5

共 10 条

[1] Byrne Michael, 2019, Biol Blood Marrow Transplant, V25, pe344, DOI 10.1016/j.bbmt.2019.06.036
[2] Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy
Chow, Victor A.
Gopal, Ajay K.
Maloney, David G.
Turtle, Cameron J.
Smith, Stephen D.
Ujjani, Chaitra S.
Shadman, Mazyar
Cassaday, Ryan D.
Till, Brian G.
Tseng, Yolanda D.
Warren, Edus H.
Shustov, Andrei R.
Menon, Manoj P.
Bhark, Sandra
Acharya, Utkarsh H.
Mullane, Erin
Hannan, Lindsay M.
Voutsinas, Jenna M.
Gooley, Ted A.
Lynch, Ryan C.
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (08) : E209 - E213
[3] Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
Jaglowski, Samantha
Hu, Zhen-Huan
Zhang, Yiyun
Kamdar, Manali
Ghosh, Monalisa
Lulla, Premal
Sasine, Joshua
Perales, Miguel-Angel
Hematti, Peiman
Nikiforow, Sarah
Steinert, Patricia
Jeschke, Margit
Yi, Lan
Chawla, Raghav
Pacaud, Lida
Horowitz, Mary M.
Bleickardt, Eric
Pasquini, Marcelo C.
[J]. BLOOD, 2019, 134
[4] Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Locke, Frederick L.
Ghobadi, Armin
Jacobson, Caron A.
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan O.
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John M.
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick
Flinn, Ian W.
Farooq, Umar
Goy, Andre
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Chavez, Julio C.
Herrera, Alex F.
Bartlett, Nancy L.
Wiezorek, Jeffrey S.
Navale, Lynn
Xue, Allen
Jiang, Yizhou
Bot, Adrian
Rossi, John M.
Kim, Jenny J.
Go, William Y.
Neelapu, Sattva S.
[J]. LANCET ONCOLOGY, 2019, 20 (01) : 31 - 42
[5] Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
Logue, Jennifer M.
Zucchetti, Elisa
Bachmeier, Christina A.
Krivenko, Gabriel S.
Larson, Victoria
Ninh, Daniel
Grillo, Giovanni
Cao, Biwei
Kim, Jongphil
Chavez, Julio C.
Baluch, Aliyah
Khimani, Farhad
Lazaryan, Aleksandr
Nishihori, Taiga
Liu, Hien D.
Pinilla-Ibarz, Javier
Shah, Bijal D.
Faramand, Rawan
Coghill, Anna E.
Davila, Marco L.
Dholaria, Bhagirathbhai R.
Jain, Michael D.
Locke, Frederick L.
[J]. HAEMATOLOGICA, 2021, 106 (04) : 978 - 986
[6] Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Nastoupil, Loretta J.
Jain, Michael D.
Feng, Lei
Spiegel, Jay Y.
Ghobadi, Armin
Lin, Yi
Dahiya, Saurabh
Lunning, Matthew
Lekakis, Lazaros
Reagan, Patrick
Oluwole, Olalekan
McGuirk, Joseph
Deol, Abhinav
Sehgal, Alison R.
Goy, Andre
Hill, Brian T.
Vu, Khoan
Andreadis, Charalambos
Munoz, Javier
Westin, Jason
Chavez, Julio C.
Cashen, Amanda
Bennani, N. Nora
Rapoport, Aaron P.
Vose, Julie M.
Miklos, David B.
Neelapu, Sattva S.
Locke, Frederick L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3119 - +
[7] Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S.
Locke, F. L.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D. B.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O. O.
Siddiqi, T.
Lin, Y.
Timmerman, J. M.
Stiff, P. J.
Friedberg, J. W.
Flinn, I. W.
Goy, A.
Hill, B. T.
Smith, M. R.
Deol, A.
Farooq, U.
McSweeney, P.
Munoz, J.
Avivi, I.
Castro, J. E.
Westin, J. R.
Chavez, J. C.
Ghobadi, A.
Komanduri, K. V.
Levy, R.
Jacobsen, E. D.
Witzig, T. E.
Reagan, P.
Bot, A.
Rossi, J.
Navale, L.
Jiang, Y.
Aycock, J.
Elias, M.
Chang, D.
Wiezorek, J.
Go, W. Y.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (26) : 2531 - 2544
[8] CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel
Neelapu, Sattva S.
Rossi, John M.
Jacobson, Caron A.
Locke, Frederick L.
Miklos, David B.
Reagan, Patrick M.
Rodig, Scott J.
Lekakis, Lazaros J.
Flinn, Ian W.
Zheng, Lianqing
Milletti, Francesca
Chang, Edmund
Xue, Allen
Plaks, Vicki
Kim, Jenny J.
Bot, Adrian
[J]. BLOOD, 2019, 134
[9] Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy
Oak, Jean
Spiegel, Jay Y.
Sahaf, Bita
Natkunam, Yasodha
Long, Steven R.
Hossain, Nasheed
Mackall, Crystal L.
Kong, Katherine A.
Miklos, David B.
[J]. BLOOD, 2018, 132
[10] Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)
Pasquini, Marcelo C.
Locke, Frederick L.
Herrera, Alex F.
Siddiqi, Tanya
Ghobadi, Armin
Komanduri, Krishna V.
Hu, Zhen-Huan
Dong, Hua
Hematti, Peiman
Nikiforow, Sarah
Steinert, Patricia
Purdum, Anna
Horowitz, Mary M.
Hooper, Michelle
Kawashima, Jun
Jacobson, Caron A.
[J]. BLOOD, 2019, 134

← 1 →